恩华药业
(002262)
| 流通市值：216.82亿 | | | 总市值：249.17亿 |
| 流通股本：8.84亿 | | | 总股本：10.16亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,470,988,804.69 | 3,010,121,701.84 | 1,510,888,789.07 | 5,697,633,044.59 |
| 营业收入 | 4,470,988,804.69 | 3,010,121,701.84 | 1,510,888,789.07 | 5,697,633,044.59 |
| 二、营业总成本 | 3,262,994,941.65 | 2,233,759,335.62 | 1,172,507,853.52 | 4,403,872,157.26 |
| 营业成本 | 1,072,024,051.65 | 745,240,827.98 | 382,394,251.04 | 1,506,540,854.61 |
| 税金及附加 | 55,676,213.86 | 38,848,380.09 | 18,793,598.74 | 75,294,786.77 |
| 销售费用 | 1,413,751,262.79 | 970,836,971.35 | 508,324,720.5 | 1,984,746,692.33 |
| 管理费用 | 223,590,309.61 | 149,497,318.11 | 74,119,812.54 | 258,761,700.49 |
| 研发费用 | 512,688,666.43 | 335,745,711.7 | 192,009,616.75 | 595,654,957.65 |
| 财务费用 | -14,735,562.69 | -6,409,873.61 | -3,134,146.05 | -17,126,834.59 |
| 其中:利息费用 | 1,978,782.77 | 1,245,123.48 | 674,955.24 | 4,025,878.2 |
| 其中:利息收入 | 17,242,845.09 | 7,667,885.24 | 4,267,518.34 | 22,254,894.13 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 47,009,834.9 | 32,479,568.44 | 20,732,489.07 | 65,568,560.11 |
| 资产处置收益 | 36,035.92 | 41,856.14 | - | 293,968.27 |
| 资产减值损失(新) | -8,321,337.04 | -9,759,417.62 | -5,816,551.85 | -39,070,467.15 |
| 信用减值损失(新) | -10,522,733.85 | -12,275,473.85 | -18,071,053.83 | -34,573,542.62 |
| 其他收益 | 9,109,331.2 | 6,007,398.82 | 3,376,275.16 | 50,594,206.07 |
| 四、营业利润 | 1,245,304,994.17 | 792,856,298.15 | 338,602,094.1 | 1,336,573,612.01 |
| 加:营业外收入 | 2,101,833.53 | 927,674.44 | 245,370.06 | 4,654,010.5 |
| 减:营业外支出 | 13,849,595.69 | 5,379,891.72 | 2,516,310.82 | 44,539,189.09 |
| 五、利润总额 | 1,233,557,232.01 | 788,404,080.87 | 336,331,153.34 | 1,296,688,433.42 |
| 减:所得税费用 | 129,031,463.73 | 88,349,794.88 | 35,691,518.93 | 155,896,130.58 |
| 六、净利润 | 1,104,525,768.28 | 700,054,285.99 | 300,639,634.41 | 1,140,792,302.84 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,104,525,768.28 | 700,054,285.99 | 300,639,634.41 | 1,140,792,302.84 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,106,047,401.4 | 700,494,742.07 | 300,705,740.93 | 1,143,564,427.44 |
| 少数股东损益 | -1,521,633.12 | -440,456.08 | -66,106.52 | -2,772,124.6 |
| 扣除非经常损益后的净利润 | 1,108,638,677.3 | 699,469,413.13 | 299,831,895.84 | 1,143,544,949.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.09 | 0.69 | 0.3 | 1.13 |
| (二)稀释每股收益 | 1.09 | 0.69 | 0.3 | 1.13 |
| 八、其他综合收益 | - | - | - | -5,881,155.37 |
| 归属于母公司股东的其他综合收益 | - | - | - | -5,881,155.37 |
| 九、综合收益总额 | 1,104,525,768.28 | 700,054,285.99 | 300,639,634.41 | 1,134,911,147.47 |
| 归属于母公司股东的综合收益总额 | 1,106,047,401.4 | 700,494,742.07 | 300,705,740.93 | 1,137,683,272.07 |
| 归属于少数股东的综合收益总额 | -1,521,633.12 | -440,456.08 | -66,106.52 | -2,772,124.6 |
| 公告日期 | 2025-10-25 | 2025-07-30 | 2025-04-19 | 2025-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |